John H. Johnson
John H. Johnson is a recognized leader in the biopharmaceutical industry with more than three decades of experience. He currently serves as the Chief Executive Officer if Reaction Biology, a biotechnology company. Prior to Reaction Biology, he was the CEO of Strongbridge Biopharma plc prior to its acquisition by Xeris Biopharma Holdings. Mr. Johnson has held executive management roles at leading global corporations, including Johnson & Johnson, where he spent the majority of career. He served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Mr. Johnson also served as President of Eli Lilly & Company’s Worldwide Oncology Unit, following the company’s 2008 acquisition of ImClone Systems, Inc., where he served as CEO and a member of ImClone’s Board of Directors. John is also an experienced Director having served on numerous boards across industry, biotech, and biopharmaceutical services companies. Mr. Johnson serves on the Boards of Axogen (AXGN), and Verastem Oncology (VSTM).
Mr. Johnson holds a BS from East Stroudsburg University of Pennsylvania.
Committee Roles:
Member of the Nominating Governance Committee